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Previous studies have shown that serotonin neurons play an important role in the induction and maintenance
of L-DOPA-induced dyskinesia in animals with lesion of the nigrostriatal dopamine system. Patients with
Parkinson’s disease that receive transplants of foetal ventral mesencephalic tissue, the graft cell preparation is
likely to contain, in addition to dopamine neurons, serotonin neurons that will vary in number depending on
the landmarks used for dissection. Here, we have studied the impact of grafted serotonin neuronsçalone or
mixed with dopamine neuronsçon the development of L-DOPA-induced dyskinesia in rats with a partial
6-hydroxydopamine lesion of the host nigrostriatal projection. In these rats, which showed only low-level
dyskinesia at the time of transplantation, serotonin grafts induced a worsening in the severity of dyskinesia
that developed during continued L-DOPA treatment, while the dopamine-rich graft had the opposite, damp-
ening effect.The detrimental effect seen in animals with serotonin neuron grafts was dramatically increased
when the residual dopamine innervation in the striatum was removed by a second 6-hydroxydopamine lesion.
Interestingly, rats with grafts that contained a mixture of dopamine and serotonin neurons (in  2:1) showed
am a r k e dr e d u c t i o ni nL-DOPA-induced dyskinesia over time, and the appearance of severe dyskinesia induced
by the removal of the residual dopamine innervation, seen in the animals with transplants of serotonin neurons
alone, was blocked.FosB expression in the striatal projection neurons, which is associated with dyskinesias, was
also normalized by the dopamine-rich grafts, but not by the serotonin neuron grafts.These data indicate that
as long as a sufficient portion, some 10^20%, of the dopamine innervation still remains, the increased host
serotonin innervation generated by the grafted serotonin neurons will have limited effect on the develop-
ment or severity of L-DOPA-induced dyskinesias. At more advanced stages of the disease, when the dopamine
innervation of the putamen is reduced below this critical threshold, grafted serotonin neurons are likely to
aggravate L-DOPA-induced dyskinesia in those cases where the dopamine re-innervation derived from the
grafted neurons is insufficient in magnitude or do not cover the critical dyskinesia-inducing sub-regions of the
grafted putamen. We conclude that it is not the absolute number of serotonin neurons in the grafts, but
the relative densities of dopamine and serotonin innervations in the grafted striatum that is the critical factor
in determining the long-term effect of foetal tissue graft, beneficial or detrimental, on dyskinesia in grafted
Parkinson’s disease patients.
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Introduction
Dyskinesia is a problematic side-effect of L-DOPA therapy
in patients with Parkinson’s disease and has also emerged
as a potentially serious adverse effect induced by dopamine
(DA) neuron transplants in patients that have undergone
cell replacement therapy (Freed et al., 2001; Hagell et al.,
2002; Olanow et al., 2003). In the clinical trials conducted
so far, the effect of foetal DA neuron transplants on
L-DOPA-induced dyskinesia has been variable. In some
patients a significant reduction has been observed, while in
others the dyskinesias have been unaffected or even made
worse (Widner et al., 1992; Defer et al., 1996; Hagell et al.,
1999; Hauser et al., 1999; Brundin et al., 2000). Moreover,
in two placebo-controlled double-blind trials (Freed et al.,
2001; Olanow et al., 2003), a significant number of grafted
patients have developed off-state dyskinesias not present
before transplantation. These results have come as a sur-
prise to scientists working with foetal cell transplantation
in animal models of Parkinson’s disease since the experi-
mental work has indicated that functional DA neuron grafts
should be quite effective in dampening L-DOPA-induced
dyskinesias in the rat Parkinson’s disease model (Lee et al.,
2000; Steece-Collier et al., 2003; Carlsson et al., 2006, 2007;
Lane et al., 2006; Maries et al., 2006). Prior to the reports
from the double-blind trials, no signs of graft-induced
dyskinesias had ever been observed or reported in either
rodent or primate models of Parkinson’s disease. Notably,
however, none of the transplant studies in rat and monkey
Parkinson’s disease models that formed the basis for the
clinical trials had been performed in L-DOPA-treated and
dyskinetic recipients.
Previous studies have suggested that discrepancies in
the composition of the grafts, the inclusion of serotonin
neurons in the graft cell preparation, in particular, may
contribute to the variable outcome in grafted Parkinson’s
disease patients (Carlsson et al., 2007). In addition to DA
neurons, the ventral mesencephalic (VM) tissue grafts
are known to contain also serotonin neurons, and the
number of these cells can vary greatly depending on the
landmarks used for dissection. When present in larger
numbers serotonin neurons are effective in inducing a
widespread serotonergic hyperinnervation of the host stri-
atum (Takeuchi et al., 1991; Wright et al., 1991; Ishida
et al., 1998; Carlsson et al., 2007), and in rats with
already established L-DOPA-induced dyskinesias. We have
shown that serotonin neuron transplants will induce a
progressive worsening of dyskinesia over time, without
any improvement in the underlying parkinsonian motor
impairments (Carlsson et al., 2007).
Serotonin neurons are particularly interesting since they
have the ability to synthesize, store and release DA, formed
from exogenous L-DOPA, but due to the lack of any
autoregulatory feedback control the DA released from
serotonin terminals will show excessive swings in response
to repetitive, intermittent L-DOPA treatment (Arai et al.,
1994, 1995; Maeda et al., 2005; Carta et al., 2007). Such
dysregulated release of L-DOPA-derived DA is likely to be
the main trigger of dyskinesia in L-DOPA-primed animals
(Carta et al., 2007), and may also play a role in Parkinson’s
disease patients undergoing long-term L-DOPA therapy
(de la Fuente-Fernandez et al., 2001, 2004). Serotonin
neurons, if present in large numbers in the graft cell
preparation, may thus have a detrimental effect on the
development of L-DOPA-induced dyskinesias in grafted
patients, and possibly also make the patients more prone
to develop graft-induced off-state dyskinesias.
The present study was designed to clarify the impact of
serotonin neuron-containing foetal tissue grafts, in the pres-
ence or absence of DA neurons, on the evolution of dyskine-
sia in L-DOPA-primed rats with partial 6-hydroxydopamine
(6-OHDA) lesions of the nigrostriatal DA system, i.e. in rats
that exhibit no or low-level L-DOPA-induced dyskinesia at
the time of transplantation. After a 3-month period of con-
tinued L-DOPA treatment these same rats received a second
6-OHDA lesion aimed at removing the remaining forebrain
DA projection, and in some cases also a lesion of the host
serotonin system, so as to simulate the situation when grafted
patients experience a severe loss of residual DA neurons, in
combination with or without a concomitant loss of seroto-
nin neurons. The results show that grafted serotonin neurons
indeed can induce a severe worsening of L-DOPA-induced
dyskinesias in previously non-dyskinetic or mildly dyskinetic
rats, but that the effect is critically dependent on the pres-
ence or absence of a spared DA innervation, and the extent
of the graft-derived DA innervation, in the host striatum.
Materials and Methods
Animals
A total of 198 adult female Sprague–Dawley rats (225–250g; B&K
Universal, Stockholm, Sweden) were used, and housed under
standard 12:12h light:dark cycle and ad libitum access to food
and water. All surgical and behavioural procedures were approved
by the Ethical Committee for use of laboratory animals in the
Lund-Malmo ¨ Region.
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 Experimental design
The experiment was conducted in three stages, as outlined in
Fig. 1.
In Stage I (induction phase) all animals received a unilateral
intrastriatal 6-OHDA lesion in order to achieve a partial deple-
tion of the nigrostriatal DA pathway (Kirik et al., 1998). About
5–6 weeks later the animals were screened using amphetamine-
induced rotation (2.5mg/kg) and 129 rats that exhibited more
than six fullbody turns/min, towards the lesioned side, were
selected and treated daily with L-DOPA (6mg/kg, s.c., Research
Organics, Cleveland, OH, USA) in combination with the decar-
boxylase inhibitor benserazide hydrochloride (10mg/kg; Sigma-
Aldrich) for 25 days to induce stable abnormal involuntary
movements (AIMs). Out of 80 animals that exhibited AIMs,
60 animals with a generally low level of dyskinesia (total mean
integrated AIM scores: 152 10) were included in the study and
allocated into four balanced groups. In addition, five L-DOPA-
naı ¨ve rats [Les-Ctrl (Drug-Naı ¨ve)] were included as a second
control group. About 12–14 weeks post-lesion, three of the
groups received single cell suspension grafts containing either
serotonin neuroblasts (5-HT, n=16), DA neuroblasts (DA narrow,
n=15) or a mixture of DA and serotonin neuroblasts (DA wide,
n=15), obtained from the VM region of E14 rat embryos, as
described (Carlsson et al., 2007). The fourth group was sham-
operated and included as control [Les-Ctrl (L-DOPA, n=14)].
In addition, 10 animals that had not developed any dyskinesia
during the L-DOPA treatment (AIM score=0) were included in
the study; half of them received grafts of serotonin neuroblasts,
as above [Non-Dys (5-HT)], while the other five were sham-
operated [Non-Dys (Sham)].
In Stage II the L-DOPA treatment was reinstated 1 week after
transplantation at a maintenance regimen of twice-weekly injec-
tions (maintenance phase), in the four dyskinetic groups and
the two ‘non-dyskinetic’ animal groups, while the Les-Ctrl (Drug-
Naı ¨ve) animals received saline injections. AIMs were evaluated
at 3, 6 and 10 weeks after transplantation, followed by assess-
ment of graft-induced functional recovery in the cylinder and
amphetamine-induced rotation tests.
In Stage III, 14 weeks after transplantation, half of the animals
in the DA narrow, DA wide, 5-HT and Les-Ctrl (L-DOPA) groups
and all 10 ‘non-dyskinetic’ animals in the Non-Dys (5-HT) and
Non-Dys (Sham) groups, received a second 6-OHDA lesion,
this time in the medial forebrain bundle (MFB), in order to
completely remove the nigrostriatal pathway. The other half,
and all animals in the Les-Ctrl (Drug-Naive) group, received
only a sham-operation, as a burr hole in the skull. After a
2-week drug-free period daily L-DOPA treatment (6mg/kg)
was resumed for an additional 14 days and occurrence of
dyskinesias was analysed at days 1, 7 and 14. Forelimb use
in the cylinder test, and tests of rotation and dyskinesia in
response to either L-DOPA or apomorphine, were performed
at 5–6 weeks after the MFB lesion (at 19–20 weeks after
grafting). The rats in the Non-Dys (5-HT) and Non-Dys (Sham)
groups received, at 8 weeks after the MFB injection, an injec-
tion of 5,7-dihydroxytryptamine (5,7-DHT) into the MFB, in
order to deplete the intrinsic serotonin system in the striatum
on the lesion and grafted side, and tested for L-DOPA-and
apomorphine-induced dyskinesia and rotation. The brains were
processed for immunohistochemistry at 21 or 25 weeks post-
grafting.
Fig. 1 Experimental design. In Stage I all animals received a unilateral intrastriatal 6-OHDA lesion in order to obtain a partial lesion of
the nigrostriatal DA pathway. Animals displayed46 fullbody turns/min, towards the lesioned side in the amphetamine (amph) rotation
test were selected.These animals, excluding five rats that were included as a saline control group [Les-Ctrl (Drug-Nai«ve)], were treated daily
with L-DOPA (6mg/kg; in combination with 10mg/kg benserazide hydrochloride) for 25 days to induce stable dyskinesia (Induction phase).
Sixty animals that displayed low levels of dyskinesia (total mean integrated AIM scores:152 10) were finally included in the study and
allocated into four balanced groups. At12^14 weeks after the first intrastriatal DA lesion, three of the groups received single cell
suspension grafts (Trpl ), containing serotonin neuroblasts (5-HT, n=16), DA neuroblasts (DA narrow, n=1 5) ,oram ixt ureofD Aand
serotonin neuroblasts (DA wide, n=15).The fourth group was sham-operated and included as a dyskinetic control group [Les-Ctrl (L-DOPA),
n=14)]. In Stage II twice-weekly L-DOPA treatment was reinstated1week after transplantation (Maintenance phase), in the four dyskinetic
groups, while the Les-Ctrl (Drug-Nai«ve) animals receive vehicle. In this stage dyskinesias were evaluated at 3, 6 and 10 weeks after
transplantation surgery. In Stage III, half of the animals in the DA narrow, DA wide, 5-HTand Les-Ctrl (L-DOPA) groups received a second
6-OHDA lesion, in the medial forebrain bundle (MFB), in order to completely lesion the nigrostriatal pathway, while the other half
[and all animals in the Les-Ctrl (Drug-Naive)] received only a sham-operation. After a 2-week drug-free period daily L-DOPA treatment
(6mg/kg) was resumed for an additional14 days and dyskinesias were evaluated at days1, 7 and14. L-DOPA-, apomorphine (apo)- and
amphetamine (amph)-induced rotation tests, as well as forelimb use in the cylinder test, were performed at different time-points
after lesion and transplantation, as indicated.
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 Toxin le sion s
Toxin injections were conducted under general anaesthesia (20:1
mixture of Fentanyl and Dormitor, i.p.). For the first partial DA
lesion 28mg of 6-OHDA (3.5mg/ml, free base, in 0.2mg/ml
ascorbic acid; Sigma–Aldrich), was distributed over four sites
in the striatum (7mg/site) at (i) AP: +1.3mm, ML:  2.6mm;
(ii) AP: +0.4mm, ML:  3.2mm; (iii) AP:  0.4mm, ML:
 4.2mm; (iv) AP:  1.3mm, ML:  4.5mm, all  5.0mm below
the dura and tooth-bar set at 0.0. For the second, complete DA
lesion, 14mg of 6-OHDA (3.5mg/ml, free base) was injected into
the MFB at AP:  4.4mm, ML:  1.2mm from bregma,  7.8mm
below dura; tooth-bar:  2.4. The serotonin lesions were performed
by injecting 10mg 5,7-DHT creatine sulphate (5mg/ml, free base;
Sigma-Aldrich), dissolved in 0.02% ascorbic acid into the
MFB at AP:  3.0mm and ML:  1.6mm, from bregma,
 7.8mm below dura; tooth-bar:  3.3. All injections were made
at a rate of 1ml/min, and the needle was kept in place for
additional 3min before retracted.
Tr ansplant ation surg er y
The graft cell preparations were obtained from E14 rat embryos
and prepared as described in Carlsson et al. (2007), with the
exception that the rostal and caudal landmarks for the DA
narrow grafts were moved about 0.5mm rostral, in order to
minimize the inclusion of serotonin neuroblasts. The DA narrow,
DA wide and 5-HT cell suspensions had a final adjusted con-
centration of 128000, 130000 and 120000 cells/ml, respectively.
The rats were mounted in the stereotaxic frame with a 5ml
Hamilton syringe fitted with a glass capillary (ø 60–80mm).
About 120000–130000 cells were injected as two 0.5ml depos-
its, at DV  5.0mm and  4.0mm (below dura), through a single
needle penetration, at AP: +0.2mm and ML:  3.5mm; tooth-bar:
0.0. After the second deposit the syringe was kept in place for an
additional 3min before retracted. Using trypan blue viability
staining in a counting chamber, the cell viability of all cell
suspensions after transplantation was estimated to 495%.
Behavioural analyses
Drug-induced rotation
Rotation in response to amphetamine (2.5mg/kg, i.p.), apo-
morphine (0.05mg/kg, s.c.) or L-DOPA (6mg/kg, s.c.) was
recorded in automated rotometer bowls (AccuScan Instrument
Inc., Columbus, OH, USA) over 90min (for amphetamine and
L-DOPA) or 60min (for apomorphine) and expressed as net full
body turns per minute, with negative values indicating rotation
away from the lesion side.
Cylinder test
Spontaneous forelimb use was evaluated in the cylinder test
(Schallert and Tillerson, 1999; Kirik et al., 2001). The rats were
placed individually in a glass cylinder (20cm in diameter), and
video filmed while performing 20–25 weight-shifting movements
of the forepaws in contact with the cylinder wall. The numbers of
left or right forepaw contacts were scored by an observer blinded
to the animals’ identity and presented as left (impaired) touches
in percentage of total touches. Normal rats will score 50% in
this test.
L-DOPA-induced dyskinesia
AIMs, resembling peak-dose dyskinesias in patients, were induced by
daily injections of L-DOPA methyl ester (6mg/kg, s.c., with 10mg/kg
benserazide hydrochloride; Sigma-Aldrich), and shifted to a main-
tenance regimen of twice-weekly L-DOPA injections at the same dose
(6mg/kg) for 16 weeks (Stages I–II). A new 2-week daily L-DOPA
challenge was performed after the second 6-OHDA lesion (Stage III).
Pre-grafting scores were calculated as means of three consecutive
tests (3 days apart) and the 3, 6 and 10 weeks post-grafting scores
as means of two test sessions (4 days apart). The post-MFB lesion
scores, at days 1, 7 and 14, are from single observations.
The AIMs were scored every 20min (for at least 3h, until no AIMs
were observed) according to a rat dyskinesia scale, where severity
scores from 0 to 4 were given for four dyskinetic subtypes accord-
ing to topographic distribution as forelimb, orolingual, axial and
locomotive behaviours, as described by Lee et al. (2000), with minor
modifications (Winkler et al., 2002; Carlsson et al., 2006). In the rat
model, the first components to appear after L-DOPA treatment are
the limb and orolingual dyskinesias. As the chronic treatment con-
tinuous the axial dyskinesias get more and more apparent. In ani-
mals with intrastriatal lesions, where the dyskinesia is less severe
as compared to a MFB lesion, the limb and orolingual dyskinesias
are the main behaviours observed after L-DOPA treatment. Animals
with MFB lesions (where the DA denervation is more complete)
develop more severe dyskinesias and the axial component becomes
more prominent. While the limb and oroligual movements are viewed
as hyperkinesia, the axial component is clearly of a different, dystonic
type. Enhanced normal behaviours, such as grooming, gnawing, rear-
ing and sniffing, could be observed, but these were not included in
the rating. The data are presented as integrated AIM scores, calcu-
lated as the area under the curve over the whole test session.
Apomorphine-induced dyskinesia
Dyskinesias induced by apomorphine (0.05mg/kg; Sigma–Aldrich)
were assessed at 20 weeks after transplantation and for the
‘non-dyskinetic’ groups [Non-Dys (5-HT) and Non-Dys (Sham)]
at 3 weeks after the 5,7-DHT lesion. AIMs were scored every
10 mins for 90 mins, using the same rating scale as for L-DOPA-
induced dyskinesia, and presented as the integrated AIM score
for the whole observation period.
Histological analyses
At 21–25 weeks post-transplantation (5 weeks after the 5,7-DHT
lesion in the ‘non-dyskinetic’ groups) the animals were anesthetized
by an overdose of sodium pentobarbital, and perfused transcardially
with 50ml saline, followed by 250ml of ice-cold 4% PFA in 0.1M
phosphate buffer (pH 7.2–7.6). The brains were postfixed in the same
fixative for 2–3h, placed in 25% sucrose for at least 24h and sectioned
on a freezing microtome at 35mm. The sections were divided into
eight series and stored (at  20 C) until further processing.
Immunohistochemistry
Immunostainings were performed as described (Carlsson et al.,
2007) using primary antibodies against tyrosine hydroxylase [TH;
mouse anti-TH (MAB318, 1:2000; Chemicon)], serotonin trans-
porter [SERT; mouse anti-SERT (MAB1564, 1:1000; Chemicon)],
serotonin [rabbit anti-serotonin (1:10000; Immunostar Inc.)] and
FosB [goat anti-FosB (SC-48X, 1:15000; Santa Cruz)], with
appropriate secondary antibodies (for TH and SERT: horse
P a g e4o f1 8 Brain (2008) T .Carlsson et al.
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 anti-mouse BA2001; for serotonin: goat anti-rabbit BA1000; and for
FosB: horse anti-goat BA9500; Vector Laboratories). SERT staining
was intensified by addition of nickel ammonium (2.5mg/ml) in the
3,30-diaminobenzidine solution. For FosB staining, 0.25% Triton
X100 was added in all steps, including rinses. To minimize back-
ground, the FosB antibody was diluted 1:50 and pre-incubated with
untreated forebrain sections (from control rats) for 3–5h.
Stereology
The number of TH- and serotonin-positive cells present in
the transplants were estimated using the Computer Assisted
Stereological Toolbox (CAST) module in VIS software
(Visiopharm A/S, Denmark) and a 60  magnification oil lens
(numerical aperture: 1.40) as described (Kirik et al., 1998;
Carlsson et al., 2007). The total numbers of cells were estimated
according to the optical fractionator (West, 1999).
Estimation of TH and SERT-positive fibre densities
TH- and SERT-positive fibre densities were determined by optical
density measurements from the stained sections using the Image
J software platform version 1.38  for Mac OSX (National Insti-
tutes of Health, USA, http://rsb.info.nih.gov/ij/) as described
(Carlsson et al., 2007). Measurements were made from the rostral
(Ros) and caudal (Cau) parts of the head of the caudate–putamen,
including two sub-areas, the rostro–dorsolateral (Rdl) and caudal-
lateral (Cl) regions, as illustrated in Fig. 8A and F, and expressed
as per cent of the control side. The Ros and Rdl values give the
means of two sections from the rostral striatum (AP: +1.60 and
+1.00), and the Cau and Cl values of two sections from the caudal
striatum (AP: +0.20mm and  0.30) (Paxinos and Watson, 2005).
Estimations of FosB-positive cell numbers
To evaluate changes in FosB expression in the striatal target neurons
as i n g l eL-DOPA injection was given at 48h before sacrifice. The total
number of FosB-positive cells was evaluated by Image J software. Two
high-resolution images were captured, corresponding to the rostral
and caudal aspect of the head of striatum (1.00 and  0.30mm from
bregma) using Scanscope GL system with Imagescope v8.2 software.
T h es a m ef o u rs t r i a t a lr e g i o n sa sa b o v e( Ros, Rdl, Cau and Cl) were
analysed. A threshold was set to exclude basal grey matter background
staining, and the total number of cells that appeared with higher
optical density was automatically calculated by the software.
Statistical analysis
All statistical group comparisons were conducted using one-way
ANOVAs, Two-way repeated measures ANOVA or un-paired
t-test where appropriate. Post hoc analyses were performed using
Dunnett’s test or Tukey HSD analysis. For all comparisons
statistical significance was set at P 0.05, and the significant
statistics are reported in respective figure legend. All compari-
sons were performed using JMP Statistical software version 5.0.1.2
(SAS Institute Inc., Cary, NC, USA).
Results
The experiment was conducted in three stages (Fig. 1).
In Stage I, 129 rats with partial, intrastriatal 6-OHDA
lesions were given daily injections of L-DOPA (6mg/kg,
plus 10mg/kg benserazide) for 25 days to develop a stable
level of L-DOPA-induced dyskinesia. All animals exhibited
46 turns/min in the amphetamine rotation test (2.5mg/kg),
which is consistent with a 70–90% loss of the nigral DA
neurons (Kirik et al., 1998; Winkler et al., 2002; Breysse
et al., 2007). In Stage II, 60 of the L-DOPA-treated rats
that had developed a low level of L-DOPA-induced dys-
kinesia (total AIM scores 152 10) were allocated to four
balanced groups that received intrastriatal grafts contain-
ing either DA neurons only (DA narrow, n=15); serotonin
neurons only (5-HT, n=16); a mixture of DA and sero-
tonin neurons (DA wide, n=15); or sham surgery [Les-Ctrl
(L-DOPA), n=14]. An additional 10 rats that showed
no signs of dyskinesia at the end of the 25-days L-DOPA
treatment period (AIM score=0) were given serotonin
neuron transplants [Non-Dys (5-HT), n=5] or sham sur-
gery [Non-Dys (Sham), n=5]. All rats received continued
L-DOPA treatment (6mg/kg, twice weekly) and the changes
in L-DOPA-induced AIMs were monitored over the subse-
quent 10 weeks. In Stage III half of the animals in each of
the four first groups, and all 10 rats in the ‘Non-dyskinetic’
groups, received a second 6-OHDA injection, this time in
the MFB, in order to remove the remaining neurons of the
nigrostriatal DA pathway. The impact of this second lesion
on the severity of the L-DOPA-induced dyskinesias was
monitored during 14 days of daily L-DOPA treatment,
starting 2 weeks after the MFB lesion.
At sacrifice, one animal in the DA narrow and one in the
5-HT graft group were found to have large necrotic tissue
damages in the cortex, and one animal in the DA wide
group had a misplaced graft extending into the ventral
forebrain. These animals were excluded from the study.
Development of L-DOPA-induced dyskinesia
in rats with advancing degeneration of the
nigrostriatal DA pathway
The rats were selected in the pre-test (in Stage I) to
exhibit a low level of L-DOPA-induced dyskinesia prior to
transplantation. In Stage II the non-transplanted lesioned
controls [Les-Ctrl (L-DOPA)] remained mildly dyskinetic
after continued L-DOPA treatment, with AIMs limited to
repetitive limb and orolingual movements, without any
signs of axial (torsive head, neck and trunk) movements
(filled circles in Fig. 2A-A00). In animals with DA-rich grafts
dyskinesias were almost completely suppressed (79 and 57%
reduction in limb and orolingual AIMs at 10 weeks after
transplantation in the DA narrow and DA wide groups,
respectively) (open and filled squares in Fig. 2A-A00). Rats
with serotonin neurons grafts, by contrast, showed a
marked, 2.5-fold, increase in the magnitude of L-DOPA-
induced dyskinesia (open triangles in Fig. 2A). This increase
was most prominently due to the appearance of the more
severe, dystonia-like axial component, not seen in any of
the other groups (Fig. 2A00).
In Stage III the residual dopaminergic forebrain projec-
tions were removed by an additional injection of 6-OHDA
Serotonin-neuron-induced dyskinesia Brain (2008) Page 5 of18
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 placed in the MFB. After a 2-week recovery period daily
L-DOPA treatment was resumed for 14 days. In the non-
grafted animals [Les-Ctrl (L-DOPA)] this resulted in a
marked increase not only in the overall magnitude of
L-DOPA-induced dyskinesia, as reflected in about 4-fold
increase in the total integrated AIM scores (filled circles in
Fig. 2B and B0), but also in increased severity, as shown by
the appearance of axial dyskinetic movements (Fig. 2B00).
In the DA narrow and DA wide graft groups the dyskinesia
scores also increased over the 2-week L-DOPA treatment
period, but the magnitude remained much below that
seen in the non-transplanted animals, and the develop-
ment of the dystonia-like axial dyskinesias was effectively
suppressed (open and filled squares in Fig. 2B-B00). In the
rats with serotonin grafts (5-HT) dyskinesias were drama-
tically increased, from a level of 398 112 in total
integrated AIM scored prior to the second lesion, to
1122 144 after the continued L-DOPA treatment (open
triangles in Fig. 2B-B00). This increase was accompa-
nied by the development of severe axial dyskinesia in all
Fig. 2 Impact of DA and serotonin grafts with advancing DA neurodegeneration (Stages II and III). L-DOPA-induced dyskinesia was
evaluated before (pre) and at 3, 6 and10 weeks after the transplantation surgery (A^A00).The Les-Ctrl (L-DOPA) group maintained the
low magnitude of dyskinesias throughout. In the DA-rich grafts (DA narrow and DA wide)t h et o t a lA I M ss c o r e sw e r ep r o g r e s s i v e l y
reduced over time, reaching 79 and 57% reduction at10 weeks respectively, while the serotonin-only graft animals (5-HT)s h o w e d
an overall 2.5-fold increase (A^A00). In the 5-HT graft group the more severe axial, dystonia-like, component, not observed in any of
the other groups, became evident at 3 weeks and further increase over the following weeks (A00). After the second 6-OHDA lesion
(in the MFB) daily L-DOPA treatment was re-instated for 2 weeks, and L-DOPA-induced dyskinesia was evaluated at days1, 7 and14 (B^B00).
In the Les-Ctrl (L-DOPA) g r o u pt o t a lA I M ss c o r ew e r ei n c r e a s e d ,u pt o4- f o l d( B), seen as an increase in the limb and orolingual AIMs, and
as the appearance of the more severe, dystonia-like, axial component (B0 and B00). Although dyskinesia showed some increase over time
in the DA narrow and DA wide graft groups, the overall AIMs scores remained on a low-to-moderate level.The 5-HT graft group, in
contrast, showed a dramatic increase after the MFB lesion, with AIMs scores reaching levels exceeding1000, which was marked higher
than seen in any of the lesion controls.The groups receiving only sham-operation at the time of the second 6-OHDA lesion, showed
no change in dyskinesia compared to their own10-week post-transplantation scores (C^C00). Asterisk indicates the different from
Les-Ctrl (L-DOPA) group (a sum of dyskinesias at 6 and10 weeks were calculated). A, A0,A 00,B ,B 0 and B00:O n e - w a yA N O V A s
F(3,56)=14.35, F(3,56)=12.56, F(3,56)=11.76, F(3,27)=15.71, F(3,56)=7 .21and F(3,27)=22.15, respectively.For all comparisons
P 0.0004. All ANOVAs were followed by Dunnett’s control test.
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 serotonin-grafted animals (Fig. 2B00). In contrast, in the
animals that received a sham-operation instead of the
second 6-OHDA lesion, dyskinesias remained unchanged
over the L-DOPA treatment period, as compared with the
10-weeks time-point (Fig. 2C-C00).
Development of dyskinesia in
non-dyskinetic rats
In Stage II of the experiment ten L-DOPA-treated but non-
dyskinetic 6-OHDA lesioned rats received either serotonin
neuron grafts [Non-Dys (5-HT), n=5] or sham surgery
[Non-Dys (Sham), n=5] (Fig. 3A). These rats developed no
signs of dyskinesia during the 25-day L-DOPA priming
period (in Stage I), and they all remained essentially
non-dyskinetic during the second period of L-DOPA treat-
ment (Post Trpl, Fig. 3B). After the second 6-OHDA lesion,
in the MFB, performed 2-weeks post-transplantation, both
groups developed severe L-DOPA-induced dyskinesia with
mean integrated AIM scores of 918 220 and 786 152 for
the Non-Dys (5-HT) and Non-Dys (Sham) groups, respec-
tively (Post MFB lesion in Fig. 3B), as well as marked
turning behaviour in response to low doses of either
apomorphine or L-DOPA (Fig. 3D and E).
To assess the role of the intrinsic serotonin neurons
for the induction of dyskinesia in these animals, the
selective serotonin neurotoxin 5,7-DHT was injected into
the MFB 8 weeks after the second 6-OHDA lesion, in
order to remove the intrinsic forebrain serotonin affer-
ents on the lesion and grafted side (Fig. 3F and G).
Fig. 3 Effect of serotonin grafts, and lesion of the intrinsic serotonin system, in L-DOPA-treated but non-dyskinetic animals. In order
to investigate the effect of serotonin grafts in the presence or absence of an intrinsic serotonin innervation,‘non-dyskinetic’ animals,
i.e. 6-OHDA lesioned rats that did not show any signs of dyskinesia after the 25-dayinduction phase, were transplanted with serotonin
grafts or sham-operated and later the intrinsic serotonin fibres were removed by a 5,7-DHT injection in the MFB (A: Experimental design;
B: Post Intrastriatal Lesion). After the transplantation [Non-Dys (5-HT)]o rs h a ms u r g e r y[ Non-Dys (Sham)] none of the animals displayed
any notable increase in dyskinesia (B: Post Trpl). However, after the second 6-OHDA lesion, placed in the MFB, both groups displayed
severe AIMs of all sub-categories (B: Post MFB lesion).Following the 5,7-DHT lesion dyskinesias in the sham-operated group were
completely abolished, while the dyskinesias seen in the serotonin graft group [Non-dys (5-HT)]r e m a i n e du n c h a n g e d( B: Post 5,7-DHTlesion).
In agreement, L-DOPA-inducedrotation was completely abolished in the sham-operated rats, butunchanged in the serotonin transplanted
animals (E). In contrast to the dyskinesias and rotation induced by L-DOPA, apomorphine-induced dyskinesias and rotation were both
unaffected by the serotonin lesion (C and D). SERT immunohistochemistry revealed an almost complete denervation of the serotonin
fibres in the striatum after the 5,7-DHT lesion (7.2 4.4% of intact side, F), while the transplanted animals showed extensive
re-innervation (108.4 18.2% of intact side, G). Scale bar in F represents 3mm. Asterisk indicates the different from post MFB.
B: One-way ANOVAs: F(3,19)=21.22, P50.0001and F(3,19)=26.96, P50.0001for and Non-Dys (Sham) and Non-Dys (MFB), respectively.
E: t-test, P=0 . 045 .
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 Consistent with previous data (Carta et al., 2007) L-DOPA-
induced (but not apomorphine-induced) dyskinesia was
completely abolished in the Non-Dys (Sham) animals, but
remained unchanged in the animals with serotonin neuron
grafts in the Non-Dys (5-HT) group (Post 5,7-DHT lesion in
Fig. 3B and C). In the rotation test L-DOPA-induced
turning was completely abolished in the non-grafted Non-
Dys (Sham) animals (0.1 0.1 turns/min) but remained at
a high level ( 14.0 3.5 turns/min) in the serotonin graft
group (Fig. 3E). Postsynaptic DA receptor supersensitivity,
as reflected in the apomorphine-induced turning response
(Fig. 3D), was unaffected by the 5,7-DHT lesion.
Impact on postsynaptic receptor
supersensitivity
In order to monitor changes in postsynaptic DA receptor
supersensitivity in the lesioned and grafted animals, dys-
kinesia and rotational behaviour in response to a low dose
of the mixed D1/D2 agonist apomorphine (0.05mg/kg, s.c.)
were assessed at 19–20 weeks post-transplantation (Fig. 4).
In rats with partial lesions, apomorphine-induced dyskine-
sias (limb and orolingual AIMs) were reduced by 81–86%
in the two DA neuron containing graft groups (DA narrow
and DA wide), as compared to the non-grafted Les-Ctrl
group, while the 5-HT graft group remained unchanged
(Fig. 4A, Intrastriatal+Sham). In the animals that had
received the second 6-OHDA lesion, the dyskinesias
increased 2- to 3-fold in both the lesion controls and in
the 5-HT graft group, but remained unchanged, or on
a low level, in the DA neuron-containing graft groups
(Fig. 4A, Intrastriatal+MFB).
Similar changes were evident in the apomorphine-
induced rotation test (Fig. 4B). Apomorphine-induced
rotation, in the direction contralateral to the lesion,
was minimal or absent in the partially lesioned animals
(Intrastriatal+Sham), but became apparent after the second
6-OHDA lesion (Intrastriatal+MFB). The increased rota-
tion seen after the second lesion in the lesion controls,
from 0.0 0.1 to  7.0 1.0 turns/min, was blocked by
the DA neuron containing grafts. The 5-HT graft group,
by contrast, showed a 2-fold higher apomorphine-induced
rotation, compared with the lesioned controls [Les-Ctrl
(L-DOPA)], after the second 6-OHDA lesion.
In the L-DOPA-induced rotation test, the animals with
partial lesions showed only minimal response to the
L-DOPA (Fig. 4C, Stage II: Intrastriatal+Sham). After the
second lesion the animals in the Les-Ctrl (L-DOPA)
group displayed an increased rotation, from 0.1 0.1 to
 1.8 1.0 turns/min. Strikingly, the 5-HT graft animals
showed an average 6.5-fold higher rotation rate (from
 0.5 0.3 to  11.4 2.1 turns/min) as compared to the
lesion control group, while the response was completely
suppressed in the two DA graft groups (Fig. 4C).
The apomorphine-induced rotation indicates that the
increase in postsynaptic DA receptor supersensitivity that
Fig. 4 Impact of DA and serotonin grafts on DA receptor supersensitivity with advancing DA neurodegeneration. Apomorphine-induced
dyskinesia (A)a n dr o t a t i o n( B)a sw e l la sL-DOPA-induced rotation (C) were assessedin order to monitor the developmentof postsynaptic
DA receptor supersensitivity in the lesioned and grafted animals. In rats with partial lesions (Intrastriatal + Sham), apomorphine-induced
dyskinesias (limb and orolingual AIMs) were reduced by 81^86% in the two DA neuron containing graft groups (DA narrow and DA wide),
as compared with the non-grafted Les-Ctrl group, while the 5-HT graft group remained unchanged (A). In the animals that had received
t h es e c o n dD Al e s i o n( Intrastriatal + MFB), dyskinesias increased several-fold in both the lesion controls and in the 5-HT graft group,
but remained unchanged, or on a low level, in the DA neuron-containing graft groups. In animals with intrastriatal lesion only
(Intrastriatal + Sham) rotation induced by apomorphine or L-DOPAwere not observed in either of the groups after the intrastriatal
6-OHDA lesion, however the serotonin graft group (5-HT) showed a tendency to increasein rotation away from the lesion side (B and C).
After the second DA lesion (Intrastriatal+MFB), apomorphine- and L-DOPA-induced rotations increased in both the Les-Ctrl (L-DOPA)
and 5-HT groups, but effectively repressed in the DA narrow and DA wide groups (B and C). Interestingly, L-DOPA-induced rotation
showed a dramatic, 6.5-fold increase in the 5-HT graft group compared to the lesion only controls (C). Asterisk indicates different from
Les-Ctrl (L-DOPA) group. A^C: One-way ANOVAs F(3,28)=11.82/F(3,27)=24.35, P50.0001and F(3,28)=10.37/F(3,27)=21.05, P50.0001
and F(3,28)=3.77 , P50.023/F(3,27)=22.91, P50.0001for Intrastriatal+Sham/Intrastriatal+MFB and A^C, respectively. All ANOVAs
were followed by Dunnett’s control test.
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 developed in the lesioned controls after the second lesion
was differentially affected by the two types of graft: nor-
malized in the rats with DA neuron containing grafts,
but made worse by the serotonin neuron transplants.
Graft-induced functional improvement
The turning bias seen in the amphetamine rotation test,
present in all animals before transplantation, was com-
pletely reversed in the two DA graft groups, but not in
the 5-HT graft group after grafting (Fig. 5A). Similarly, the
left forelimb use in the cylinder test, which was reduced to
510% in the lesion control animals, was restored to normal
performance in the DA narrow and DA wide graft groups
(54.7 6.5% and 55.6 6.7% of intact side, respectively)
but unaffected by the 5-HT grafts (9.9 4.7% of intact side;
Fig. 5B). Together, these data indicate that functional DA
release, accompanied by reversal of DA receptor super-
sensitivity was restored in the grafted striatum in the two
groups that had received DA neuron-containing transplants.
However, the functional recovery induced by the DA-rich
grafts, seen in Stage II (Fig. 5B), was partially lost after the
second 6-OHDA lesion (Fig. 5C), which is consistent with
previous findings (Breysse et al., 2007). Amphetamine-
induced rotation after the second 6-OHDA lesion was not
evaluated in the current study, however, previous data have
shown that recovery in rotation by DA neuron grafts in
partial DA lesioned rats is not effected by a second complete
lesion placed in the MFB (Breysse et al., 2007).
Changes in striatal FosB expression
In order to monitor postsynaptic changes in the striatal
target neurons in the L-DOPA-treated dyskinetic animals,
FosB-protein expression in the striatum was evaluated
48h after the last L-DOPA injection. The number of FosB-
positive cells, which is known to be strongly correlated
with the magnitude of L-DOPA-induced dyskinesia in the
rat model (Andersson et al., 1999; Winkler et al., 2002),
were counted in the rostral (Ros) and caudal (Cau) stria-
tum, as well as in two sub-regions, the rostro–dorsolateral
(Rdl) and Caudal-lateral (Cl) areas of the striatal head
(Fig. 8A).
In the animals with partial lesions of the nigrostriatal
DA pathway, i.e. the animals that had received intrastriatal
6-OHDA followed by a sham injection in the second sur-
gery (Intrastriatal+Sham in Fig. 6A–D), FosB was expres-
sed in a large number of cells on the lesion side, ranging
from 926 177 to 1579 168 cells in all four regions
analysed (Fig. 6A–D, open bars). The animals in the DA
graft groups (DA narrow and DA wide) had significantly
lower numbers of FosB-positive cells in all four regions
(grey bars in Fig. 6A–D), ranging from 136 32 to
517 103, similar to the number observed on the non-
lesioned side (averages of number of cells on the intact side,
 SD, are indicated by the full and dashed horizontal lines
in Fig. 6A–D). In the 5-HT graft group the FosB-positive
cell number tended to exceed that seen in the dyskinetic
Les-Ctrl (L-DOPA) controls (from 1381 242 to 2164 316
Fig. 5 Functional impact of DA and serotonin grafts.Changes in amphetamine-induced rotation were assessed at11weeks post-grafting
(A), and forelimb use in the cylinder test at12 weeks post-grafting (B) and at 5 weeks after the second DA lesion (C). After the first,
intrastriatal, lesion all groups displayed a strong amphetamine-induced rotational bias ipsilateral to the lesion side. Following transplan-
tation the rotation in the DA narrow ( 0.2  0.8 turn/min) and DA wide (0.7 0.9 turn/min) groups were completely reversed back to
normal, while the 5-HTand the Les-Ctrl (L-DOPA) groups were unaffected (19.3 2.3 and18.5 1.8 turn/min, respectively). In the cylinder
test, which evaluates the rats’ spontaneous forelimb use, all groups were severely impaired and balanced prior to transplantation
(Les-Ctrl (L-DOPA):1 1 . 1 2.0%, DA narrow:1 2.5 3.9%, DA wide:1 1 .5 2.6% and 5-HT:8 . 7 2.9% of intact side). After transplantation
the DA neuron graft groups were reversed back to normal performance (DA narrow:5 4 . 7 6.5% and DA wide:5 5 . 6 5.7% of intact).
The 5-HT (9.9 4.7% of intact) and the Les-Ctrl (L-DOPA) (6.1 1.9% of intact) groups were unaffected.The second 6-OHDA lesion,
however, partly removed the beneficial effect seen in the cylinder test in the DA grafted animals. Dashed lines in B and C represent
the performance of a normal, unbiased, animal. Asterisk indicates different from respective pre-value. (AçB) Two-way repeated
measures ANOVAs:Time interactions, F(3,53)=97 .99, P50.001 and F(3,53)=62.40, P50.0001, respectively.
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 Fig. 6 Effect of DA and serotonin grafts on striatal FosB expression.FosB-positive cells were estimated in the striatum in four
areas corresponding to the rostral, rostro^dorsolateral (Rdl),Caudal and Caudal-lateral (Cl) striatum (Fig. 8A). In the dyskinetic
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 cells in the four regions analysed; black bars in Fig. 6A–D).
These differences, however, did not reach significance.
In the animals that received the second 6-OHDA
injection (Intrastriatal+MFB in Fig. 6A–D), FosB expres-
sion was further increased in the non-grafted controls
[Les-Ctrl (L-DOPA)], from 1471 241 to 2674 526 cells.
Similar high expression levels were observed in all regions
in the 5-HT graft group (from 1838 311 to 2962 613
cells). The animals in the DA graft groups displayed
significantly lower expression of FosB protein, in partic-
ular in the Rdl (524 183 and 390 170 cells) and Cl
(372 122 and 431 179 cells) regions, which were not
different from that seen on the contralateral intact side
(DA narrow: P40.11, in all regions; DA wide: P40.14,
in all regions, un-paired t-tests).
Interestingly, in the lesioned control animals FosB-
expressing cells were found mainly in the completely DA
denervated areas, as determined from adjacent TH stained
sections (Fig. 6E). Following the second 6-OHDA lesion the
head of striatum was almost completely devoid of TH-
positive innervation and the FosB expressing cells were
widely distributed over large areas of the striatum (Fig. 6F).
In the DA narrow and DA wide groups FosB expression was
completely normalized in the areas reinnervated by the
graft-derived TH-positive fibres (Fig. 6G and H). In the
5-HT graft group the graft-derived serotonin innervation
was unable to reverse FosB expression; both the number
and staining intensity of the FosB-positive cells tended to
be increased, above that seen in the lesion-only controls,
in the areas innervated by the graft-derived serotonin fibres
(compare Fig. 6I and J with E and F).
In the non-dyskinetic animals, that received an addi-
tional unilateral serotonin lesion, the serotonin trans-
planted group [Non-Dys (5-HT)] tended to increase in
FosB expression in all regions in striatum (ranging from
1893 620 to 4149 1034), as compared to the sham-
operated group [Non-Dys (Sham)], from 1038 134
to 2761 669. This was observed in particular in the
Rdl part [2499 477 versus 1265 158 in the Non-dys
(5-HT) and Non-dys (Sham), respectively, P=0.06,
un-paired t-test]. However, the cell numbers in both
groups were comparable to respective dyskinetic group,
Non-Dys (5-HT) versus 5-HT group (P40.28 for all
regions, un-paired t-test) and Non-Dys (Sham) versus
Les-Ctrl (L-DOPA) group (P 0.14 for all regions,
un-paired t-test).
Histological analysis of graft survival and
fibre outgrowth
TH and serotonin immunohistochemistry revealed sur-
viving grafts in all transplanted animals (Fig. 7A and F).
The DA narrow grafts contained high numbers of
TH-positive cells, 3621 459 (3822 825 and 3419 466
in Intrastriatal+Sham and Intrastriatal+MFB respec-
tively, P=0.68, un-paired t-test), but virtually devoid
of any serotonin-positive neurons. Conversely, the 5-HT
graft group contained high numbers of serotonin
neurons, 2256 308 (1860 298 and 2709 540 in
Intrastriatal+Sham and Intrastriatal+MFB, respectively,
P=0.20, un-paired t-test), with very few TH-positive
cells, 19 4 (11 4 and 29 6i nIntrastriatal+Sham
and Intrastriatal+MFB, respectively, P=0.04, un-paired
t-test). The DA wide grafts, in contrast, included high
numbers of both DA, 3633 501 (2510 524 and
4355 798 in Intrastriatal+Sham and Intrastriatal+MFB,
respectively, P=0.16, un-paired t-test), and serotonin
neurons, 2307 325 (1929 260 and 2686 585 in Intras-
triatal+Sham and Intrastriatal+MFB, respectively, P=0.27,
un-paired t-test), with an average DA:serotonin neuron
ratio of 1.8:1.
The intrastriatal 6-OHDA lesion depleted the TH-
positive fibres in the caudal striatum by more than 90%,
while the rostral region was partly spared ( 20% of
normal; Figs 7B–E and 8A). The second 6-OHDA lesion
removed the spared fibres in the whole striatum (Figs 7B–E
and 8B). In the DA narrow and DA wide graft groups, the
transplanted DA neurons restored TH-positive fibre density
in the caudal striatum by 12–14% of normal, while the
rostral parts were overall poorly innervated (Ros: 3–5%,
Rdl: 6–9% of intact side; Figs 7B–E, 8C and D).
lesion control animals [Les-Ctrl (L-DOPA)] extensive FosB expression were observedin allregions after the firstintrastriatal 6-OHDA lesion
(Intrastriatal + Sham; A^D) and was further increased after the second DA lesion (Intrastriatal+MFB; A^D). Increased FosB expression
was mainly observed in DA denervated areas, as seen in the rostro^dorsolateral and caudal regions in the lesion control group after
the intrastriatal lesion (E), and further also in the rostral region after the second 6-OHDA lesion (F).The serotonin neuron-containing
grafts (5-HT) did not show an overall significant increase in FosB expression as compared to the lesion-only controls [Les-Ctrl (L-DOPA)];
individual cases, however, showed a clear tendency to an increase in both number, distribution and staining intensity of the
FosB-expressing cells, as illustrated in I and J.The DA graft groups (DA narrow and DA wide), in contrast, reversed FosB expression
in all regions after the first lesion (Intrastriatal + Sham), and expression in the rostro^dorsolateral and caudal areas, close to the grafted
DA cells, were effectively repressed also after the second 6-OHDA lesion (Intrastriatal + MFB; B^D,G and H). However, in the rostral
striatum, which were poorly innervated byTH-positive fibres from the graft, the protein expression were not different from the Les-Ctrl
(L-DOPA) group (Intrastriatal + MFB; A).The horizontal lines in A^D represent the average cell number (full) 1S D( das hed)ont hei ntact
side (all animals in respective region and lesion). Insets give the total AIM scores for the illustrated animals. Scale bars in J represent1mm.
Asterisk indicates different from Les-Ctrl (L-DOPA) group. A: One-way ANOVA F(3,28)=10.71, P=0.0001intrastriatal + MFB;B - D :O n e - w a y
ANOVAs F(3,28)=12.53, P50.0001, F(3,28)=18.61, P50.0001and F(3,28)=19.03, P50.0001/F(3,27)=9.29, P=0.0003, F(3,27)=5.95,
P=0.004 and F(3,27)=10.03, P=0.0002 for Intrastriatal + Sham/Intrastriatal + MFB and B^D, respectively. All ANOVAs were followed
by Dunnett’s control test.
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 SERT immunohistochemistry showed that the intrastria-
tal 6-OHDA lesion had caused a minor damage (19–23%)
to the serotonin innervation in the striatum (Figs 7G, I and
8F). The second DA lesion led to an additional loss of
about one-third of the SERT-positive striatal serotonin
innervation, to 66–69% of intact side in the rostral and
caudal striatum (Figs 7G–J and 8G). In the 5-HT and the
DA wide groups, which contained high numbers of
serotonin neurons in their grafts, a marked SERT-positive
hyperinnervation was observed at all levels investigated
(Figs 7G–J, 8I and J). This hyperinnervation was partic-
ularly prominent in the Rdl region, where the density
of SERT-positive fibres was increased to 178–237% and
Fig. 7 TH- and serotonin-positive cell numbers and TH- and
SERT-positive fibre innervation in the striatum.The total number
of grafted TH- and serotonin-positive cell in the striatum was
estimated using stereological technique (A and F).The DA narrow
grafts contained high numbers of TH-positive cells (3621 459)
without inclusion of serotonin-positive neurons, and the 5-HT
graft group contained high numbers of serotonin neurons
(2256 308), with very fewTH-positive cells (19 4). In the DA
wide grafts, high numbers of bothTH-positive (3633 501) and
serotonin-positive neurons (2307 325), were found.The extent
of TH- and SERT-positive fibre innervation was determined, by
optical density measurements from theTH and SERTstained
sections, for the rostral and the caudal aspect of the head of the
striatum, and two sub-regions, representing Rostro^dorsolateral
(Rdl) and Caudal-lateral (Cl) areas (illustrated in A and F in Fig. 8).
The initial intrastriatal 6-OHDA lesion depleted theTH-positive
fibres in the rostral striatum with  80%, while in the caudal
striatum  90% of the DA fibres were lesioned (B and D,
Intrastriatal + Sham).The spared fibres in the rostral region were
mainly located in the medial and ventral parts of the striatum,
and the rostro^dorsolateral regions of the striatum showed
less than10% spared fibres (C, Intrastriatal + Sham).The second
6-OHDA lesion removed the remaining DA fibres and54% of
normal innervation remained in the four regions evaluated
(B^E, Intrastriatal + MFB). In the DA narrow and DA wide groups
significant TH-positive fibre reinnervation ( 12^14% of normal)
was observed around the graft, in the caudal and caudal-lateral
regions (D and E).The first 6-OHDA lesion resulted in a marginal
loss of the serotonin fibres ( 20%; G^J, Intrastriatal+Sham).
The second lesion further removed an additional  10% of the
SERT-positive fibres (to  70% of intact side) in the striatum
(G^J, Intrastriatal + MFB). In the 5-HTand DA wide groups an
extensive SERT-positive hyperinnervation was evident in the
striatum at all levels (143^238% and139^246% of intact side in
the intrastriatal + Sham and intrastriatal + MFB groups respectively;
G^J). In contrast, the DA narrow group, which contained no
serotonin neurons, showed no increased SERT-positive innervation
at any level. Ash indicate different from other groups; Asterisk
indicate different from Les-Ctrl (L-DOPA) group. A and F:O n e - w a y
ANOVAs F(2,42)=30.30, P50.0001and F(2,42)=25.13, P50.0001
respectively; D and E:O n e - w a yA N O V A sF(3,28)=2.91, P=0 . 05
and F(3,28)=3.55, P=0 . 03 /F(3,28)=4.85, P=0.009 and
F(3,28)=5.19, P=0 . 007forIntrastriatal + Sham/Intrastriatal + MFB
and D and E,r e s p e c t i v e l y ;( G^J)O n e - w a yA N O V A s
F(3,28)=1 1.73, P50.0001, F(3,28)=9.04, P=0.0003, F(3,28)=16.69,
P50.0001and F(3,28)=13.59, P50.0001/F(3,27)=8.47 , P=0.0005,
F(3,27)=13.83, P50.0001, F(3,27)=9.05, P=0.0003 and
F(3,27)=8.28, P=0.0006 for Intrastriatal + Sham/Intrastriatal + MFB
and G^J, respectively. All ANOVAs were followed byTukey HSD
analysis (A and F) or Dunnett’s control test (B^E,G^J).
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 171–260% of intact side in the 5-HT and DA wide graft
groups, respectively (Fig. 7H).
Interestingly, a localized SERT-positive serotonin hyper-
innervation was observed in the ventrolateral region of the
caudal striatum in a significant number (9 of 14) of the
non-transplanted animals in the dyskinetic lesion control
groups (asterisk in Fig. 8F and G), both in the animals
receiving the second 6-OHDA lesion (Intrastriatal+MFB;
2 of 7) as well as in the animals receiving only the partial,
intrastriatal lesion (Intrastriatal+Sham; 7 of 7). This effect
was also observed in the DA narrow group, (10 of 14;
Fig. 8H) as well as the Drug-Naı ¨ve (i.e. non-L-DOPA-
treated) lesion control animals (3 of 5). This serotonin
hyperinnervation, however, did not correlate with either
the magnitude of dyskinesia, or with the pattern of FosB
expression, suggesting that this sprouting response may
be induced by the 6-OHDA lesion, independent of any
L-DOPA treatment. Indeed, close comparison of adjacent
SERT and FosB stained sections showed that regions of
increased density of SERT-positive fibres displayed only
low numbers of FosB-expressing cells.
Discussion
The study was designed to investigate the influence of
serotonin neuron-containing grafts on the development
of L-DOPA-induced dyskinesia in chronically L-DOPA-
treated rats with partial 6-OHDA lesions of the nigro-
striatal DA pathway, that had developed no or only
low-level dyskinesias at the time of transplantation. Three
months later, the rats were subjected to a second 6-OHDA
lesion, in order to simulate the situation in grafted, mildly
dyskinetic patients when the degeneration of the intrinsic
DA system has progressed further. In Parkinson’s disease
patients, disease progression is accompanied by a progres-
sive worsening of the L-DOPA-induced peak-dose dyskine-
sias and a reduction of the therapeutic window of L-DOPA
medication (Mouradian et al., 1990; Obeso et al., 2000).
Similarly, the low-level dyskinesia seen in the partially
lesioned rats (in Stages I and II of the experiment)
increased both in magnitude and severity when the resid-
ual striatal DA innervation was removed by the second
lesion (Stage III). The DA neuron-rich grafts had a marked
dampening effect on dyskinesia present at the time of
transplantation, as seen earlier (Lee et al., 2000; Steece-
Collier et al., 2003; Carlsson et al., 2006, 2007; Lane et al.,
2006; Maries et al., 2006), and they were also able to
block the increase in dyskinesia induced by the second
DA lesion, as well as the increase in striatal FosB expres-
sion that is closely linked to the development of dyskine-
sia in L-DOPA-treated animals. In the DA narrow and
DA wide graft groups dyskinesias remained on a low-to-
moderate level, also after removal of the remaining DA
afferents, without any clear signs of the more severe,
dystonia-like axial dyskinesias (for further explanation of
the axial component see Materials and Methods section).
Dyskinesia induced by direct stimulation of postsyn-
aptic DA receptors by a low dose of apomorphine was
almost completely eliminated. The results obtained in the
amphetamine-induced rotation and forelimb-use tests, as
well as the normalization of DA receptor supersensitivity
in the apomorphine rotation test, indicate that a functional
DA innervation had been re-established from the grafted
DA neurons in these rats.
The changes induced by serotonin-rich grafts were quite
different: The low-level dyskinesia present in the partially
lesioned rats at the time of transplantation increased after
transplantation in the 5-HT group, as reflected in an
average 2-fold increase in total AIM score and the
appearance of the more severe, dystonia-like, axial dys-
kinesia during Stage II of the experiment. Further, there
was a dramatic increase in both the magnitude and sever-
ity of dyskinesia after the second DA lesion (Stage III).
The serotonin transplants did not induce any functional
improvement in the amphetamine-induced rotation and
cylinder tests, the postsynaptic DA receptors remained
supersensitive (as assessed by the apomorphine- and
L-DOPA-induced rotation tests), and both apomorphine-
induced dyskinesia and cellular FosB expression remained
as high, or increased, compared with the dyskinetic lesion-
only controls.
Interaction of the serotonin neurons with
the spared DA innervation of the host
In the rat Parkinson model the magnitude, and also the
expression pattern, of L-DOPA-induced dyskinesia is
critically dependent on an interaction between the spared
DA innervation and the intrinsic serotonin afferents (Carta
et al., 2007). In the lesioned controls studied here the
dyskinesia scores recorded in the animals with partial
intrastriatal 6-OHDA lesions increased 3-fold when the
residual DA innervation was removed. Consistent with
previous findings (Carta et al., 2007) all components of
AIMs (orolingual, limb, axial and locomotive) were
completely eliminated by the 5,7-DHT lesion, indicating
that the dyskinetic movements were triggered almost
exclusively by DA formed and released by the intrinsic
serotonin afferents.
In rats with serotonin-rich transplants the grafted
serotonin neurons provided a widespread serotonergic
hyperinnervation of the host striatum, with a terminal
density that was up to 2.5-fold higher than normal. In the
partially lesioned rats the impact of this graft-derived
serotonergic hyperinnervation was rather modest: dyskine-
sia was increased above that seen in the lesion-only
controls, but remained at a low-to-moderate level, i.e. at
a total AIM score of below 400. Removal of the residual
intrinsic DA innervation, however, caused a dramatic
increase in both the magnitude and severity of L-DOPA-
induced dyskinesia, with the appearance of intense axial
movements, and total AIM scores that exceeded 1100.
Serotonin-neuron-induced dyskinesia Brain (2008) Page13 of18
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 Fig. 8 TH and SERT immunohistochemistry. After the first intrastriatal 6-OHDA lesion (A)t h ec a u d a lp a r to ft h es t r i a t u mw a s
severely depleted, while spared TH-positive innervation could be observed in the rostral (in particular in medial and ventral) regions.
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 These data indicate that the spared intrinsic DA innervation
has an important dampening effect on the serotonin-
dependent dyskinesias, and that DA released from serotonin
terminals is detrimental in animals where the striatum is
completely denervated. At that stage of the disease, the
serotonin terminals may be the only source of DA release in
the striatum, at least when low doses of L-DOPA are
administered as in the present experiment.
The mechanism underlying this dampening effect has
most probably both a pre and a postsynaptic component.
On the presynaptic side, the swings in extracellular levels of
L-DOPA-derived DA, released as a false transmitter from
the serotonin terminals, will be counteracted by an active
re-uptake of DA from the extracellular space by the
remaining DA terminals. In this situation the interplay
between the serotonin and DA terminals may, in fact, be
functionally beneficial in that the serotonin terminals can
provide additional sites for synthesis and storage of
L-DOPA-derived DA that can be utilized by the residual
DA terminals. On the postsynaptic side, the residual DA
innervation, with the help of the exogenously supplied
L-DOPA, will be able to maintain the postsynaptic DA
receptors in a normo-sensitive state, as indicated by the
absence of apomorphine-induced rotation in the partially
lesioned rats. The postsynaptic DA receptor supersensitivity
that developed after the removal of the remaining DA
afferents by the MFB lesion (as reflected by the marked
increase in apomorphine-induced turning and cellular FosB
expression) is likely to make the striatal neurons prone to
elicit abnormal behavioural responses.
The dysregulated, pulsatile release of DA from the graft-
derived serotonin terminals was clearly non-functional (in
the amphetamine-induced rotation and cylinder tests) and,
interestingly, also unable to normalize DA receptor super-
sensitivity (in the apomorphine-induced rotation test) and
striatal FosB expression. In situations when the residual DA
innervation has degenerated, therefore, DA released from
serotonin terminals will trigger more severe dyskinetic
responses by acting on supersensitive DA receptor sites, in
the absence of any beneficial effects of the L-DOPA
treatment.
Interaction between DA and serotonin
neurons in grafts containing a mixture
of both neuron types
In one of the transplant groups, the DA wide group, the
dissection of the VM tissue was made so as to obtain grafts
that contained both DA and serotonin neurons in large
numbers. As in our previous study (Carlsson et al., 2007)
these mixed grafts restored the TH-positive innervation in
the caudal striatum to 12–14% of normal, and increased the
host serotonin innervation to levels up to 2-fold, above
normal, in particular, in the rostro–dorsolateral part of the
striatum, and they were as efficient as the DA narrow grafts
(i.e. the transplants containing DA neurons only) in
restoring DA-dependent motor behaviour in the cylinder
and amphetamine-induced rotation tests. Most notably,
however, these mixed grafts were as efficient as the DA
neuron only grafts in the dampening of L-DOPA-induced
dyskinesia, both in partially lesioned animals (Stage II)
and after removal of the remaining host DA afferents
(Stage III).
Interestingly, the dampening effect on dyskinesia in the
rats with DA wide grafts, i.e. grafts with mixed DA and
serotonin neurons, was opposite to the worsening seen in
rats with grafts containing serotonin neurons only (i.e. the
5-HT graft group). It seems unlikely that this difference was
due to any major differences in number of serotonin
neurons in the grafts, or the extent of graft-derived
serotonin innervation of the host striatum since several of
the animals in the DA wide group, that showed marked
reductions in L-DOPA-induced dyskinesia, had similar
numbers of serotonin neurons in the graft and similar
levels of SERT-positive striatal innervation as animals in the
5-HT graft group that showed the opposite effect. This
indicates that the effect of the graft-derived serotonin
innervation is detrimental only in the absence of a
significant functional dopaminergic input. Similar to the
spared host DA innervation, as discussed above, we propose
that the DA innervation derived from the DA neurons in
the graft will be effective in blocking the pro-dyskinetic
effect of grafted serotonin neurons by a combination of
efficient re-uptake of L-DOPA-derived DA from the
extracellular space (which will help to dampen the excessive
swings in DA released from the serotonin terminals), and
reversal of postsynaptic DA receptor supersensitivity in
the re-innervated areas. This is supported by the observa-
tions that dyskinesia induced by direct stimulation of the
postsynaptic receptors, by a low dose of apomorphine,
was much reduced in the DA wide group, and that
apomorphine- and L-DOPA-induced turning, and increased
FosB expression in the striatal projection neurons, were
almost completely eliminated in the DA wide graft group
(but increased in the 5-HT graft group).
The second 6-OHDA lesion, placed in the MFB, (B) removed the remaining DA fibres and left the striatum completely denervated.
In the animals receiving DA-rich grafts (DA narrow and DA wide) aTH-positive reinnervation could be observed around the graft core
in the caudal aspect of the head of the striatum (C and D), while in the group receiving serotonin grafts (5-HT), with only few
included TH-positive neurons in the grafts, the striatum remained completely denervated (E). In the animals with serotonin-rich
grafts (5-HTand DA wide), strong hyperinnervation was observed in the whole striatum, in particular in the Rdl region (I and J).
A distinct, localized increase in SERT-positive fibres was observed in the ventrolateral striatum in many of the non-grafted lesion
controls, and in the DA narrow graft group (marked by asterisks in F, G and H). Scale bar in J represents 3mm.
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 Clinical implications
The results show that the development of L-DOPA-induced
dyskinesia in the rat Parkinson’s disease model depends on
a close interaction between the dopaminergic and sero-
tonergic afferents. In non-grafted 6-OHDA lesioned rats
systemic L-DOPA administration induces AIMs only when
the loss of DA neurons in the SN is greater than  80% and
the loss of DA innervation in the lateral part of the striatum
exceeds  90% (Winkler et al., 2002). This suggests that when
dyskinesias is induced in the rat model by low L-DOPA
doses (6–12mg/kg; which corresponds to the doses used
clinically), as little as 10% of the normal DA innervation
density in the critical, lateral dyskinesia-triggering part of
the caudate–putamen may be sufficient to buffer the swings
in DA released from the serotonin terminals. Since the DA
innervation in the intact striatum is some 15- to 20-times
higher in density than the serotonin ones (as judged by the
tissue levels of DA and serotonin; see Carta et al., 2007) this
suggests that a DA:serotonin terminal ratio of about 1:1,
or higher, would be sufficient to keep the dyskinesias in
check. Indeed, when this situation is met DA synthesized
and released from the serotonin terminals might be
beneficial and contribute positively to the therapeutic
efficacy of L-DOPA treatment. It is interesting to compare
these values, obtained in rats, with the situation in
Parkinson’s disease patients. Similar to the rat striatum
the DA:serotonin ratio in the putamen of control human
cases is about 20:1 (Kish et al., 2008). In advanced cases of
Parkinson’s disease the putaminal DA levels are typically
reduced by more than 90% (by 98% in the Kish et al., 2008
study), while the loss of putaminal serotonin innervation
(as assessed by levels of serotonin, SERT and tryptophan
hydroxylase) is less, and also more variable (30–65%). As a
result, the DA:serotonin ratio is reduced to an average of
about 1:1 (Kish et al., 2008), i.e. within the range where
dyskinesias would be expected to be held in check by the
residual DA innervation. Kish et al. did not observe any
difference in putaminal DA:serotonin ratio in patients with
or without recorded dyskinesias, which may be explained
by the fact that the tissue samples used for analysis included
the whole putamen. If the induction of L-DOPA-induced
dyskinesias is critically dependent on DA released in a
particular, dyskinesia-prone sub-region of the putamen
(as is the case in rodents; see Cenci et al., 1998) then the
overall putaminal tissue levels may mask important regional
differences in the DA and serotonin innervation densities
that may determine the patient’s sensitivity to develop
dyskinetic side-effects.
In grafted animals, we propose that the impact of
serotonin neurons in the transplant will depend on the
density of graft-derived and/or spared intrinsic DA inner-
vation in the striatum, and whether the relative density of
the serotonin innervation in the critical part of the stri-
atum will be kept below this critical threshold. In animals
with partial 6-OHDA lesions (with an overall 80–90%
reduction in striatal DA innervation) the serotonin-only
transplants (5-HT graft group) produced a 2- to 3-fold
increase in the SERT-positive innervation in the caudate–
putamen, corresponding to a DA:serotonin innervation
ratio in the range of 1:1 to 1:2. In these previously
mildly dyskinetic animals the AIMs scores increased about
2.5-fold, but were still kept in the low-to-moderate range.
In the DA wide group, transplants contained DA and
serotonin neurons in a ratio of  2:1. In these animals, the
TH-positive innervation density was  15% of normal, while
the SERT-positive innervation was increased about 2-fold
above normal, suggesting that the relative densities of the
DA and serotonin innervations of the host striatum was
maintained within the critical 1:1 range. Consequently,
these animals displayed low or no dyskinesias also after
the second 6-OHDA lesion.
The implications of these findings for the appearance of
dyskinesia in grafted Parkinson’s disease patients are 3-fold:
(i) In patients with transplants that contain DA neurons
but no or very few serotonin neurons the grafts should
retard the development of L-DOPA-induced dyskinesia, and
reduce already established dyskinesias, provided that the
graft-derived DA innervation of the host putamen is
extensive enough to exceed that of the intrinsic serotonin
innervation; (ii) In patients with grafts that contain sero-
tonin neurons in excess of the dopaminergic ones the
impact on dyskinesia will depend on the extent of degen-
eration of the host nigrostriatal system or the extent of
reinnervation of the host striatum by the graft-derived
DA neurons. The excess innervation provided by the
grafted serotonin neurons will promote the development
of L-DOPA-induced dyskinesias, and also make already
established dyskinesias worse, in case the DA innervation
of the dyskinesia-triggering sub-region of the putamen is
reduced below the critical threshold and (iii) In patients
with more advanced disease (i.e. extensive degeneration of
the intrinsic putaminal DA innervation) the impact of
mixed DA and serotonin grafts will depend on the ability
of the grafted DA neurons to provide a widespread
innervation of the host putamen, in particular of those
sub-regions of the putamen that are primarily involved in
the induction of AIMs in dyskinetic patients. Interestingly,
in a recent study of the brains of two VM-transplanted
Parkinson’s disease patients (Mendez et al., 2008) these
long-term surviving grafts were seen to contain DA and
serotonin neurons in roughly equal numbers (as assessed
by TH and tryptophan hydroxylase immunohistochemistry;
O. Isacson, personal communication). Consistent with the
observations in the DA wide graft group in the present
study, it seems that L-DOPA-induced dyskinesia had
remained low in these patients still by 21 months after
transplantation.
Although we did not observe any spontaneous graft-
induced dyskinesias in the present study, this experimental
design does not provide evidence to rule out the possibility
that serotonin neurons may play a role in the development
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 of graft-induced off-state dyskinesia in grafted patients.
Observations in transplanted patients (Freed et al., 2001;
Ma et al., 2002) and 6-OHDA lesioned rats (Steece-Collier
et al., 2003; Carlsson et al., 2006, 2007; Lane et al., 2006;
Maries et al., 2006) indicate that this type of dyskinesia
is induced by dysregulated release of DA, and/or exces-
sive activation of supersensitive DA receptors, caused
by an uneven, patchy graft-derived DA innervation of
the host striatum. It seems possible that an unfavorable
DA:serotonin innervation ratio could contribute to this
effect by maintaining the postsynaptic DA receptors in
a supersensitive state. Moreover, the excessive swings in
extracellular DA generated from graft-derived serotonin
terminals could be the driving force to induce a hyper-
sensitive state of the postsynaptic receptors that will
make the striatal targets prone to generate AIMs even in
the absence of any exogenous L-DOPA. Investigations of
the presence and extent of serotonin innervation in the
striatum of patients with graft-induced dyskinesias, e.g. by
PET imaging with ligands for the serotonin transporter,
may help to clarify this point.
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